These results suggest that delivering higher doses of weaker CAR T-cells with CD4+:CD8+ ratios of 25:75 or 50:50 kill more cancer cells and spare more healthy cells for tumors where on-target off-tumor killing is undesired or detrimental. The gene discussed is CD8A; the disease is cancer.